Validating Cell Surface Proteases as Drug Targets for Cancer Therapy: What Do We Know, and Where Do We Go?

Verhulst, Emile; Garnier, Delphine; De Meester, Ingrid; Bauvois, Brigitte

Verhulst, Emile; Garnier, Delphine; De Meester, Ingrid; Bauvois, Brigitte.

Afiliação

Verhulst E; Laboratory of Medical Biochemistry, Department of Pharmaceutical Sciences, University of Antwerp, 2000 Antwerp, Belgium.
Garnier D; Centre de Recherche des Cordeliers, Sorbonne Université, Inserm, Cell Death and Drug Resistance in Lymphoproliferative Disorders Team, F-75006 Paris, France.
De Meester I; Laboratory of Medical Biochemistry, Department of Pharmaceutical Sciences, University of Antwerp, 2000 Antwerp, Belgium.
Bauvois B; Centre de Recherche des Cordeliers, Sorbonne Université, Inserm, Cell Death and Drug Resistance in Lymphoproliferative Disorders Team, F-75006 Paris, France.

Cancers (Basel) ; 14(3)2022 Jan 26.

Article em En | MEDLINE | ID: mdl-35158891

Palavras-chave

cancer; drug resistance; function; inhibitor; protease; signalling; survival

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Bases de dados: MEDLINE Idioma: En Revista: Cancers (Basel) Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Bélgica